AB0271 COMPARISON OF DOSE REDUCTION METHODS BETWEEN RAPIDLY AND GRADUALLY DE-ESCALATION IN RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OVER 15 MONTHS

Background: However tsDMARDs and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop for de-escalation. Objectives: We analyze predictors de-escalation in RA patients treated with baricitinib over 15 months each group start 4mg/day 2mg/day. This study will assess compare (1) characteristic achieve remission (REM) low disease activity (LDA) as (2) two methods, rapidly gradually respond first-line therapy. Methods: Cases were recruited to SHin-yokohama Arthritis REgister (SHARE) between 2015 2020 (n=3,961). Patients diagnosed according ACR/EULAR 2010 classification criteria started 4mg/day(n=42) 2mg/day(n=108) months. 45 cases fulfilled EULAR definition difficult-to-treat (D2T-RA). In 150 (Male25, Female125 cases, duration 12.5+/-5.9years) Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire-Disability (HAQ-DI), anti-CCP2 clinical parameters analyzed. Two methods compared this study. stopped stable REM/LDA no swollen joint 12 weeks. decreased 50%, 42%, 28%, 14% order Results: (1)” Detect starting baricitinib” group, 17 achieved joint(40.5%), there differences RA, onset age biologics and/or JAK inhibitors naïve, titer CDAI at non-achieved cases. 2mg/day 59 (54.6%). naïve was predictor achieving joint. D2T-RA negative predictor. (2)”Comparison sustained REM LDA rate arthritis” whole patients, tapered 61 Gradually showed less relapse after (33.3% vs. 93.8%, p<0.0001). Particularly 47 32.7 80.9%, 2cases 8cases increase CDAI, all these regain increasing baricitinib. Conclusion: Tapering using may help sucseed deduction References: [1]Ann Rheum Dis 2019;78:171-178 Disclosure Interests: None declared